期刊
ITALIAN JOURNAL OF PEDIATRICS
卷 43, 期 -, 页码 -出版社
BMC
DOI: 10.1186/s13052-017-0341-4
关键词
Palivizumab; Respiratory syncytial virus; Prophilaxys; Preterm
类别
Guidelines on immunoprophylaxis for prevention of RSV infection recommend it in preterm babies born before 29 wGA; in babies affected by bronchopulmonary dysplasia or congenital heart defects; and in post-heart transplantation patients. On the contrary, immunoprophylaxis is not recommended in preterm babies born between 29 and 35 wGA. We evaluated the impact of RSV-related healthcare expenditures in infants in the first 3 years of life in Italy, Lombardy Region. In light of the collected data and considering the cost of a complete palivizumab prophylaxis, extending it to babies 29-32 wGA, aged less than 6 months, appears to be a cost-effective strategy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据